XORTX Therapeutics Inc.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.

Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested

XORTX Announces Submission to European Medicines Agency

XORTX Therapeutics Inc (NASDAQ: XRTX) has announced topline results from Part 1 of the three-part Pharmacokinetics Bridging Study – XRX-OXY-101. The data showed a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation.

Why Are XORTX Therapeutics Shares Skyrocketing Today?

The stock price of XORTX Therapeutics Inc (NASDAQ: XRTX) skyrocketed by over 90% pre-market today. This is why.

XORTX Therapeutics (XRTX) Stock: Why It Skyrocketed Over 90% Today

Clinical Trial Shows Substantially Improved Bioavailiability Clinical Trial Shows Substantially Improved Bioavailiability

XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that a type B pre-Phase 3 meeting request with the FDA was submitted on Wednesday, July 6, 2022. The meeting is expected to be held in approximately 70 days from today.

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2022, being held June 13th through 16th, 2022. Dr. Allen Davidoff, XORTX's CEO, will present an overview on the Company, including the Company's progress to date and planned future regulatory and clinical activities.

XORTX to Present at BIO International Convention 2022

CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to welcome and appoint Mr. Anthony Giovinazzo to the Board of Directors and as Chair of the Board.

XORTX Welcomes New Member to the Board of Directors and Appoints Chair

CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of Small and Medium Enterprise (“SME”) status for the European Union (the “EU”). This status is applicable for European Medicines Agency (“EMA”) related interactions and confirmed by the SME office – Regulatory Science and Innovation Task Force. SME status provides reduced costs to the Company as it initiates discussions with the US Food and Drug Administration (“FDA”) and EMA regarding the upcoming XRX-OXY-301 phase 3 registration trial for XRx-008 and other clinical programs.

XORTX Receives Small and Medium Enterprise Status for the European Union

Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program

XORTX Receives No Objection Letter from Health Canada

Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program

XORTX Announces Grant of US Patent

● Autosomal Dominant Polycystic  Kidney Disease – XRx-008 Program IND Filed ●

XORTX Files IND with US FDA

XORTX Therapeutics (NASDAQ: XRTX) shares are trading higher by 54.6% at $1.87 after the company announced the submission of a Patent Cooperation Treaty patent application seeking international patent protection for the patent entitled "Compositions and Methods for Enhancing Anti-Vi.

Here's Why XORTX Therapeutics Shares Are Rising

Compositions and Methods for Enhancing Anti-Viral Therapies Compositions and Methods for Enhancing Anti-Viral Therapies

XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Bridging Pharmacokinetic Study Initiated Bridging Pharmacokinetic Study Initiated

XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study

Synopsis of 2021 Achievements and Key Activities for 2022 Synopsis of 2021 Achievements and Key Activities for 2022

XORTX Provides Corporate Update

CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David MacDonald as Chief Technology Officer (CTO). Dr. MacDonald has an over 30-year record of achievement in drug development and leadership in pharma and biotech, achieving critical, value-inflection milestones for those companies.

XORTX Announces Appointment of Chief Technology Officer

• Increased Xanthine Oxidase Expression in ADPKD Kidneys • • Increased Xanthine Oxidase Expression in ADPKD Kidneys •

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

CALGARY, Alberta, Dec. 10, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight and announce the online publication of the peer reviewed paper entitled “Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19” in the American Journal of Nephrology and available at the link below.

XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

LAVAL, Quebec--(BUSINESS WIRE)-- #AcuteKidneyInjury--Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX's novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acu

Altasciences Chosen by XORTX Therapeutics, Inc. to Conduct Pharmacokinetic Bridging Study XRX-OXY-101 in Support of Developing New Therapies for Progressive Kidney Disease and Acute Kidney Injury

CALGARY, Alberta, Dec. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced today that James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, has initiated research coverage on XORTX.

XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners

CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the “Meeting”). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website.

XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)  Click Here  to view full Argus Equity Research Report. COMPANY HIGHLIGHTS: Excerpts (as conveyed by Argus Analyst Steve Silver) include: XRTX: Advancing Kidney Disease Therapeutics Into Late-Stage Clinical Trials In our view, XORTX has assembled a compelling pipeline of therapeutic assets with the potential to treat progressive kidney diseases.

Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)

CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, wishes to clarify that the Company's common shares were halted on both the TSX Venture Exchange (the “TSXV”) and the Canadian Securities Exchange (the “CSE”) to finalize the de-listing procedures required on the CSE.  The common shares will be de-listed from the CSE at close of market today and the common shares will re-commence trading tomorrow, Friday, November 5, on the TSXV under the trading symbol XRTX.

XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange

CALGARY, Alberta, Nov. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has received final approval from the TSX Venture Exchange (the “TSXV”) to list its common shares on the TSXV effective as of the open of market on November 4, 2021 under the share symbol XRTX.

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced the closing of an underwritten public offering of 2,906,000 units ("Units"), with each Unit consisting of one common share, no par value, and one warrant ("Warrant") to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses (the “Offering”). The common shares and warrants contained in the Units are immediately separable upon issuance. The warrants have an initial exercise price of US$4.77 per share, are immediately exercisable, and have a term of approximately five years. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 435,900 common shares and/or warrants to purchase up to an additional 435,900 common shares at the Offering price less the underwriting discounts. On October 15, 2021, A.G.P. exercised its option to purchase additional warrants to purchase up to an additional 435,900 common shares.

News for XORTX Therapeutics Inc. Stock (XRTX)